Estimation of drug cost avoidance (DCA) and pathology cost avoidance (PCA) through participation in NCIC clinical trials group (NCIC-CTG) phase III clinical trials in Canada.
Patricia A. Tang
No relevant relationships to disclose
Annette E. Hay
No relevant relationships to disclose
Christopher J. O'Callaghan
No relevant relationships to disclose
Nicole Mittmann
No relevant relationships to disclose
Carole Chambers
No relevant relationships to disclose
Joseph L Pater
No relevant relationships to disclose
Natasha B. Leighl
No relevant relationships to disclose